ABL Bio Inc. (KOSDAQ:298380)

South Korea flag South Korea · Delayed Price · Currency is KRW
182,100
-8,300 (-4.36%)
At close: Dec 17, 2025
525.77%
Market Cap10.04T
Revenue (ttm)88.44B
Net Income (ttm)-28.65B
Shares Out55.13M
EPS (ttm)-575.68
PE Ration/a
Forward PE907.07
Dividendn/a
Ex-Dividend Daten/a
Volume760,655
Average Volume1,173,242
Open190,500
Previous Close190,400
Day's Range182,100 - 190,600
52-Week Range26,400 - 220,000
Beta0.53
RSI54.90
Earnings DateFeb 6, 2026

About ABL Bio

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. ABL Bio Inc.is based in Seoul, South Korea. [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
CEO Sang Hoon Lee
Employees 102
Stock Exchange KOSDAQ
Ticker Symbol 298380
Full Company Profile

Financial Performance

In 2024, ABL Bio's revenue was 33.40 billion, a decrease of -49.04% compared to the previous year's 65.55 billion. Losses were -55.53 billion, 1998.1% more than in 2023.

Financial Statements

News

There is no news available yet.